Clinical and treatment characteristics of patients with IMC after unrelated UCBT for Hurler syndrome
| Patient . | ABO (recipient/donor) . | Preconditioning ALC, ×109/L . | Onset, d . | Lineage . | Duration, d . | Treatment . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | A+/B– | 9.14 | 73 | AIHA | 10 | Prednisolone | Resolved |
| 2* | O+/O+ | 7.08 | 69 | AIHA/ITP/AIN | 98 | Prednisolone | Second BMT |
| Rituximab bortezomib | |||||||
| 3* | O+/A+ | 6.88 | 96 | AIHA/ITP/AIN | 22 | None | Second BMT |
| 4 | O+/O+ | 7.77 | 42 | ITP/AIN | 138 | Prednisolone | Resolved |
| Rituximab (2)† | |||||||
| IVIG bortezomib (2)† | |||||||
| Mycophenolate mofetil | |||||||
| Plasma exchange | |||||||
| Etanercept | |||||||
| 5 | O+/A– | 6.67 | 22 | ITP | 38 | Prednisolone | Resolved |
| IVIG | |||||||
| Mycophenolate mofetil | |||||||
| Rituximab | |||||||
| 6 | O–/A+ | 7.66 | 70 | AIHA | 14 | Prednisolone | Resolved |
| IVIG | |||||||
| Rituximab | |||||||
| 7 | O+/O+ | 6.73 | 62 | AIHA | 215 | Prednisolone | Resolved |
| Rituximab | |||||||
| Sirolimus | |||||||
| Mycophenolate mofetil | |||||||
| Bortezomib (2)† | |||||||
| 8 | O–/O+ | 5.94 | 56 | AIHA/ITP/AIN | 144 | Prednisolone | Deceased |
| IVIG | |||||||
| Rituximab | |||||||
| Mycophenolate mofetil | |||||||
| Bortezomib | |||||||
| Vincristine | |||||||
| Cyclophosphamide | |||||||
| Plasma exchange |
| Patient . | ABO (recipient/donor) . | Preconditioning ALC, ×109/L . | Onset, d . | Lineage . | Duration, d . | Treatment . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | A+/B– | 9.14 | 73 | AIHA | 10 | Prednisolone | Resolved |
| 2* | O+/O+ | 7.08 | 69 | AIHA/ITP/AIN | 98 | Prednisolone | Second BMT |
| Rituximab bortezomib | |||||||
| 3* | O+/A+ | 6.88 | 96 | AIHA/ITP/AIN | 22 | None | Second BMT |
| 4 | O+/O+ | 7.77 | 42 | ITP/AIN | 138 | Prednisolone | Resolved |
| Rituximab (2)† | |||||||
| IVIG bortezomib (2)† | |||||||
| Mycophenolate mofetil | |||||||
| Plasma exchange | |||||||
| Etanercept | |||||||
| 5 | O+/A– | 6.67 | 22 | ITP | 38 | Prednisolone | Resolved |
| IVIG | |||||||
| Mycophenolate mofetil | |||||||
| Rituximab | |||||||
| 6 | O–/A+ | 7.66 | 70 | AIHA | 14 | Prednisolone | Resolved |
| IVIG | |||||||
| Rituximab | |||||||
| 7 | O+/O+ | 6.73 | 62 | AIHA | 215 | Prednisolone | Resolved |
| Rituximab | |||||||
| Sirolimus | |||||||
| Mycophenolate mofetil | |||||||
| Bortezomib (2)† | |||||||
| 8 | O–/O+ | 5.94 | 56 | AIHA/ITP/AIN | 144 | Prednisolone | Deceased |
| IVIG | |||||||
| Rituximab | |||||||
| Mycophenolate mofetil | |||||||
| Bortezomib | |||||||
| Vincristine | |||||||
| Cyclophosphamide | |||||||
| Plasma exchange |
All patients received FluBu conditioning.
AIHA, autoimmune hemolytic anemia; AIN, autoimmune neutropenia; BMT, bone marrow transplant; ITP, immune thrombocytopenia; IVIG, IV immunoglobulin.
Patient 2 and 3 underwent a second transplant for primary graft failure.
“(2)” refers to the number of courses of a therapy given.